InvAscent, a private equity growth capital, completed the acquisition of a minority stake in Malladi Drugs and Pharmaceuticals, a bulk drugs maker, for $33m. "InvAscent’s deep understanding of the pharma API/CDMO (contract development and manufacturing company) space and its track record as a value-adding investor will make this a mutually beneficial partnership," Prashant Malladi, Malladi Chairman.